Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802632 · ClinicalTrials.gov registry record · Phase 1
AZD9291 First Time In Patients Ascending Dose Study
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 603
- Enrollment target
NCT01802632 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 603 participants.
The verdict
NCT01802632, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 603 participants
- Enrollment target
Study Summary
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment, it will measure the levels of drug in the body, it will also measure the anti-cancer activity. By using these pieces of information together the best dose of this drug to use in further clinical trials will be selected.
Interventions
- DRUG AZD9291
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2013-03-04 |
| Est. Completion | 2023-12-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01802632
The ClinicalTrials.gov registry entry for NCT01802632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 603 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD9291 is the first listed.
NCT01802632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01802632 about?
NCT01802632 is a clinical study titled "AZD9291 First Time In Patients Ascending Dose Study". This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment. This is the first time this drug has ever been tested in patients, and so it will help to understand what...
What is the current status of trial NCT01802632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 603 participants. The study started on 2013-03-04. Estimated completion is 2023-12-11.
What interventions are being tested in trial NCT01802632?
The interventions under investigation include: AZD9291 (DRUG).
Who is sponsoring clinical trial NCT01802632?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.